Vor Biopharma (NYSE:VOR) Earns “Market Outperform” Rating from JMP Securities

JMP Securities reissued their market outperform rating on shares of Vor Biopharma (NYSE:VOR) in a report released on Friday, Benzinga reports. The firm currently has a $12.00 price objective on the stock.

Other equities analysts also recently issued research reports about the stock. Oppenheimer reissued an outperform rating and set a $10.00 target price (down previously from $15.00) on shares of Vor Biopharma in a research note on Monday, May 13th. HC Wainwright reissued a buy rating and issued a $17.50 price objective on shares of Vor Biopharma in a research note on Friday. Wedbush reaffirmed an outperform rating and set a $11.00 target price on shares of Vor Biopharma in a research note on Friday, May 10th. Finally, Barclays lowered their target price on Vor Biopharma from $10.00 to $3.00 and set an overweight rating for the company in a report on Wednesday, August 14th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Vor Biopharma has a consensus rating of Buy and an average price target of $10.92.

Vor Biopharma Trading Up 20.0 %

NYSE VOR opened at $1.09 on Friday. The firm has a market capitalization of $74.56 million, a PE ratio of -0.61 and a beta of -0.34. The business’s 50-day moving average price is $0.91 and its two-hundred day moving average price is $1.45. Vor Biopharma has a 12 month low of $0.70 and a 12 month high of $3.14.

Vor Biopharma (NYSE:VOR) last announced its earnings results on Thursday, August 8th. The company reported ($0.41) EPS for the quarter, meeting the consensus estimate of ($0.41). As a group, analysts forecast that Vor Biopharma will post -1.51 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Hsbc Holdings PLC raised its holdings in Vor Biopharma by 177.0% during the second quarter. Hsbc Holdings PLC now owns 49,038 shares of the company’s stock worth $51,000 after buying an additional 31,333 shares during the last quarter. Cubist Systematic Strategies LLC acquired a new stake in shares of Vor Biopharma in the 2nd quarter worth about $53,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Vor Biopharma in the 2nd quarter worth about $63,000. Acadian Asset Management LLC lifted its position in Vor Biopharma by 51.4% in the 2nd quarter. Acadian Asset Management LLC now owns 81,305 shares of the company’s stock valued at $79,000 after acquiring an additional 27,597 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its stake in Vor Biopharma by 48.0% during the 2nd quarter. Renaissance Technologies LLC now owns 495,300 shares of the company’s stock valued at $495,000 after purchasing an additional 160,642 shares during the last quarter. 97.29% of the stock is owned by institutional investors and hedge funds.

Vor Biopharma Company Profile

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.